000143012 001__ 143012
000143012 005__ 20240229112539.0
000143012 0247_ $$2doi$$a10.1038/s41408-019-0174-z
000143012 0247_ $$2pmid$$apmid:30696815
000143012 0247_ $$2pmc$$apmc:PMC6351644
000143012 0247_ $$2altmetric$$aaltmetric:54689225
000143012 037__ $$aDKFZ-2019-00637
000143012 041__ $$aeng
000143012 082__ $$a610
000143012 1001_ $$aKriegsmann, Katharina$$b0
000143012 245__ $$aCereblon-binding proteins expression levels correlate with hyperdiploidy in newly diagnosed multiple myeloma patients.
000143012 260__ $$aLondon [u.a.]$$bNature Publishing Group$$c2019
000143012 3367_ $$2DRIVER$$aarticle
000143012 3367_ $$2DataCite$$aOutput Types/Journal article
000143012 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1551873449_29911
000143012 3367_ $$2BibTeX$$aARTICLE
000143012 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000143012 3367_ $$00$$2EndNote$$aJournal Article
000143012 520__ $$aImmunomodulatory drugs (IMIDs) are very effective in the treatment of multiple myeloma (MM). The description of their cereblon-mediated mechanism of action was a hallmark in MM research. Although the importance of IMID-induced degradation of cereblon-binding proteins is well described in vitro, the prognostic value of their expression levels in MM cells is less clear. Based on recently published data showing somewhat conflicting RNA levels, we analyzed the association between the levels of the Ikaros family zinc finger protein 1 (IKZF1), IKZF3, and karyopherin subunit alpha 2 (KPNA2) proteins measured by flow cytometry and prognostic parameters in 214 newly diagnosed MM patients who were randomized in the GMMG HD6 trial. No statistically significant associations between the expression levels and age, gender, light chain type, International Staging System (ISS) stage or cytogenetic high- and normal risk groups could be identified. Hyperdiploid MM cells expressed significantly higher levels of IKZF1, IKZF3 and KPNA2 than nonhyperdiploid cells. In contrast, translocation t(11;14) was associated with significantly lower expression levels. In conclusion, the observed overexpression of cereblon-binding proteins in MM cells with gain of chromosomes 5, 9, 11, 15, and 19 is consistent with the previously proposed positive regulation of MYC by IKZF1 and IKZF3, as well as MYC activation in hyperdiploid MM cells.
000143012 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000143012 588__ $$aDataset connected to CrossRef, PubMed,
000143012 7001_ $$aBaertsch, Marc-Andrea$$b1
000143012 7001_ $$aAwwad, Mohamed H S$$b2
000143012 7001_ $$aMerz, Maximilian$$b3
000143012 7001_ $$aHose, Dirk$$b4
000143012 7001_ $$aSeckinger, Anja$$b5
000143012 7001_ $$aJauch, Anna$$b6
000143012 7001_ $$0P:(DE-He78)ecb33fb615e08035fdcefcaebfdff8f0$$aBecker, Natalia$$b7$$udkfz
000143012 7001_ $$0P:(DE-He78)e15dfa1260625c69d6690a197392a994$$aBenner, Axel$$b8$$udkfz
000143012 7001_ $$aRaab, Marc S$$b9
000143012 7001_ $$aHillengass, Jens$$b10
000143012 7001_ $$aBertsch, Uta$$b11
000143012 7001_ $$aDürig, Jan$$b12
000143012 7001_ $$aSalwender, Hans Jürgen$$b13
000143012 7001_ $$aHänel, Mathias$$b14
000143012 7001_ $$aFenk, Roland$$b15
000143012 7001_ $$aMunder, Markus$$b16
000143012 7001_ $$aWeisel, Katja$$b17
000143012 7001_ $$aMüller-Tidow, Carsten$$b18
000143012 7001_ $$aGoldschmidt, Hartmut$$b19
000143012 7001_ $$aHundemer, Michael$$b20
000143012 773__ $$0PERI:(DE-600)2600560-8$$a10.1038/s41408-019-0174-z$$gVol. 9, no. 2, p. 13$$n2$$p13$$tBlood cancer journal$$v9$$x2044-5385$$y2019
000143012 909CO $$ooai:inrepo02.dkfz.de:143012$$pVDB
000143012 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)ecb33fb615e08035fdcefcaebfdff8f0$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000143012 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e15dfa1260625c69d6690a197392a994$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000143012 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000143012 9141_ $$y2019
000143012 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBLOOD CANCER J : 2017
000143012 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000143012 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000143012 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000143012 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central
000143012 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal
000143012 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ
000143012 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review
000143012 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ
000143012 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000143012 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000143012 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000143012 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000143012 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000143012 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bBLOOD CANCER J : 2017
000143012 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lBiostatistik$$x0
000143012 980__ $$ajournal
000143012 980__ $$aVDB
000143012 980__ $$aI:(DE-He78)C060-20160331
000143012 980__ $$aUNRESTRICTED